http://www.medpagetoday.com/Rheumatology/Arthritis/61621?xid=NL_MBstandard_2016-11-22&eun=g721819d0r

The interleukin-6 receptor (IL-6R) blocker sarilumab given as monotherapy among patients with active rheumatoid arthritis (RA) was superior to adalimumab (Humira) monotherapy, a phase III trial found. At week 24, the mean change from baseline in Disease Activity Score in 28 joints (DAS28) was -3.28 for those randomized to sarilumab compared with -2.20 among those given adalimumab, for a difference of -1.08 (95% CI -1.36 to -0.79, P<0.0001), according to Gerd R. Burmester, MD, of Charite-University Medicine in Berlin, and colleagues. http://www.medpagetoday.com/Rheumatology/Arthritis/61621?xid=NL_MBstandard_2016-11-22&eun=g721819d0r